187 related articles for article (PubMed ID: 11063335)
1. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients.
Sagedal S; Nordal KP; Hartmann A; Degré M; Holter E; Foss A; Osnes K; Leivestad T; Fauchald P; Rollag H
Transplantation; 2000 Oct; 70(8):1166-74. PubMed ID: 11063335
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
4. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.
Conti DJ; Freed BM; Singh TP; Gallichio M; Gruber SA; Lempert N
Arch Surg; 1995 Nov; 130(11):1217-21; discussion 1221-2. PubMed ID: 7487465
[TBL] [Abstract][Full Text] [Related]
5. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
7. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
Mabilangan C; Preiksaitis J; Cervera C;
Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
[TBL] [Abstract][Full Text] [Related]
8. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
9. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
11. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
13. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.
Kletzmayr J; Kreuzwieser E; Watkins-Riedel T; Berlakovich G; Kovarik J; Klauser R
Transplantation; 2000 Oct; 70(8):1174-80. PubMed ID: 11063336
[TBL] [Abstract][Full Text] [Related]
14. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
Mabilangan C; Preiksaitis JK; Cervera C;
Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection in renal transplant recipients.
Carstens J; Andersen HK; Spencer E; Madsen M
Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients.
Vu D; Shah T; Ansari J; Sakharkar P; Yasir Q; Naraghi R; Hutchinson I; Min D
Transpl Infect Dis; 2014 Oct; 16(5):724-32. PubMed ID: 25208755
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant cytomegalovirus immunoglobulin G antibody levels could prevent severe cytomegalovirus infections post-transplant in liver transplant recipients: Experience from a tertiary care liver centre.
Gupta E; Pamecha V; Verma Y; Kumar N; Rastogi A; Hasnian N; Bhadoria AS
Indian J Med Microbiol; 2017; 35(4):499-503. PubMed ID: 29405140
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
